OptimizeRx Statistics

Total Valuation

OptimizeRx has a market cap or net worth of $321.73 million. The enterprise value is $334.12 million.

Market Cap	321.73M
Enterprise Value	334.12M

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

OptimizeRx has 18.57 million shares outstanding. The number of shares has increased by 4.07% in one year.

Current Share Class	18.57M
Shares Outstanding	18.57M
Shares Change (YoY)	+4.07%
Shares Change (QoQ)	+2.95%
Owned by Insiders (%)	14.77%
Owned by Institutions (%)	58.02%
Float	14.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	33.08
PS Ratio	3.05
Forward PS	2.96
PB Ratio	2.70
P/TBV Ratio	65.35
P/FCF Ratio	31.11
P/OCF Ratio	30.89
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 41.97, with an EV/FCF ratio of 32.31.

EV / Earnings	n/a
EV / Sales	3.19
EV / EBITDA	41.97
EV / EBIT	91.89
EV / FCF	32.31

Financial Position

The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.24.

Current Ratio	2.57
Quick Ratio	2.41
Debt / Equity	0.24
Debt / EBITDA	3.53
Debt / FCF	2.80
Interest Coverage	0.61

Financial Efficiency

Return on equity (ROE) is -8.21% and return on invested capital (ROIC) is 1.49%.

Return on Equity (ROE)	-8.21%
Return on Assets (ROA)	1.33%
Return on Invested Capital (ROIC)	1.49%
Return on Capital Employed (ROCE)	2.45%
Revenue Per Employee	$812,000
Profits Per Employee	-$76,504
Employee Count	129
Asset Turnover	0.61
Inventory Turnover	n/a

Taxes

In the past 12 months, OptimizeRx has paid $565,000 in taxes.

Income Tax	565,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +107.79% in the last 52 weeks. The beta is 1.33, so OptimizeRx's price volatility has been higher than the market average.

Beta (5Y)	1.33
52-Week Price Change	+107.79%
50-Day Moving Average	13.73
200-Day Moving Average	8.56
Relative Strength Index (RSI)	68.99
Average Volume (20 Days)	383,266

Short Selling Information

The latest short interest is 1.14 million, so 6.13% of the outstanding shares have been sold short.

Short Interest	1.14M
Short Previous Month	1.15M
Short % of Shares Out	6.13%
Short % of Float	7.95%
Short Ratio (days to cover)	5.87

Income Statement

In the last 12 months, OptimizeRx had revenue of $104.75 million and -$9.87 million in losses. Loss per share was -$0.54.

Revenue	104.75M
Gross Profit	67.45M
Operating Income	3.64M
Pretax Income	-25.32M
Net Income	-9.87M
EBITDA	7.96M
EBIT	3.64M
Loss Per Share	-$0.54

Full Income Statement

Balance Sheet

The company has $16.59 million in cash and $28.98 million in debt, giving a net cash position of -$12.39 million or -$0.67 per share.

Cash & Cash Equivalents	16.59M
Total Debt	28.98M
Net Cash	-12.39M
Net Cash Per Share	-$0.67
Equity (Book Value)	119.28M
Book Value Per Share	6.43
Working Capital	33.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $10.41 million and capital expenditures -$72,000, giving a free cash flow of $10.34 million.

Operating Cash Flow	10.41M
Capital Expenditures	-72,000
Free Cash Flow	10.34M
FCF Per Share	$0.56

Full Cash Flow Statement

Margins

Gross margin is 64.39%, with operating and profit margins of 3.47% and -9.42%.

Gross Margin	64.39%
Operating Margin	3.47%
Pretax Margin	-8.88%
Profit Margin	-9.42%
EBITDA Margin	7.60%
EBIT Margin	3.47%
FCF Margin	9.87%

Dividends & Yields

OptimizeRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.07%
Shareholder Yield	-4.07%
Earnings Yield	-3.07%
FCF Yield	3.21%

Analyst Forecast

The average price target for OptimizeRx is $11.81, which is -31.85% lower than the current price. The consensus rating is "Buy".

Price Target	$11.81
Price Target Difference	-31.85%
Analyst Consensus	Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.

Last Split Date	May 14, 2018
Split Type	Reverse
Split Ratio	1:3

Scores

OptimizeRx has an Altman Z-Score of 1.96 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	6